Hedera Dx

On #WorldCancerDay, we reaffirm our commitment to improving #CancerCare through innovation. 🔬 Advances in #PrecisionMedicine, #NGS, and #LiquidBiopsy are transforming how we monitor and treat cancer, enabling earlier and more personalized interventions. But innovation must go hand in hand with improving patients’ access—because everyone deserves the best possible care. 💙 Let’s keep pushing boundaries to #CloseTheCareGap and build a future where cancer is a manageable disease.

🌟 We’re hiring! 🌟 At Hedera Dx, our mission is simple but powerful: to empower hospitals and clinicians with cutting-edge #liquidbiopsy solutions powered by #NGS, enabling them to deliver better outcomes for #cancerpatients. We are currently looking for a Field Application Specialist based in France to join our growing team. If you’re experienced, passionate, and ready to make a real impact, we’d love to hear from you! 👉 Apply now: https://lnkd.in/eU5YqbGd Help us spread the word by sharing this post or tagging someone in your network who could be the perfect fit! 🙌

As 2024 comes to a close, we at Hedera Dx want to thank everyone — our clients who trust us 🌟, our partners who drive progress 🤝, and our competitors who inspire innovation 🔬. Together, we’ve made strides in bringing access to advanced cancer care and improving patient outcomes. As we are looking forward to 2025, we are even more committed to this work. Wishing you and your loved ones a joyous holiday season 🎄 and a prosperous, healthy, and impactful new year 🎆! #LiquidBiopsy #CancerDiagnostics #ctDNA #Oncology #PrecisionMedicine #NGS

Check our latest update to the Hedera Profiling 2 ctDNA test panel which sets a new standard for targeted, efficient, and highly sensitive blood-based molecular profiling. 🌟 Why choose Hedera Profiling 2 ctDNA test panel? 👉Compact yet comprehensive: A targeted 32-gene NGS-based panel detecting SNVs, Indels, CNVs, Fusions, and MSI across more than 10 common tumor types. 👉Exceptional analytical accuracy: Sensitivity above 97% and specificity over 99% at 0.5% VAF for ESCAT Level I somatic variants. The panel contains more than 80% of all ESCAT Level I variants currently recommended for ctDNA testing by ESMO. 👉Data-driven analytical validation: This assay is backed by a unique international study involving 78 reference samples and 137 clinical samples from 11 centers across 8 countries. Hedera Profiling 2 ctDNA test panel enables actionable insights for lung, breast, colorectal, and other common solid tumors. Visit our updated product page to learn more about this next-level ctDNA-based liquid biopsy solution: https://lnkd.in/e96tR6Bx #LiquidBiopsy #CancerDiagnostics #ctDNA #Oncology #PrecisionMedicine #NGS

November is Lung Cancer Awareness Month 💙 At Hedera Dx, we’re dedicated to transforming lung cancer care through advanced tumor profiling and longitudinal treatment monitoring using Next-Generation Sequencing (NGS) and non-invasive liquid biopsy solutions. By providing precise insights into each patient’s cancer journey, we’re helping to guide more effective treatment strategies. Together, let’s drive progress in lung cancer care! #LungCancerAwarenessMonth #PrecisionOncology #LiquidBiopsy #NGS #BloodDraw

Movember is here! 🎗️ Join us in raising awareness for men’s health, from prostate cancer prevention, to effective screening and personalized treatment. Every mustache grown and conversation started can make a difference. Let’s stand together for a healthier future! #Movember #MensHealth #ProstateCancer

🚨 New Exciting Announcement! 🚨 The manuscript, “Analytical Validation of a Pan-Cancer NGS Assay for In-House Liquid Biopsy Testing: An International Multicenter Study”, is now live on medRxiv! 🙌 With 10+ centers collaborating from 8 countries to shape this groundbreaking work, this paper is a true reflection of the power of international collaboration between institutions and the industry in order to advance the fields of liquid biopsy and precision oncology. This represents a major step forward in advancing liquid biopsy testing in hospitals, in order to support the delivery of more personalized and timely cancer care.🎗️ A big thank you to all collaborators and contributors for their hard work and dedication! 🙏 👉 Check out the full announcement here: https://lnkd.in/e_rNfJDb #LiquidBiopsy #CancerCare #PrecisionOncology #NGS #Collaboration #Innovation

This October marks Breast Cancer Awareness Month 🎗️ At Hedera Dx, we focus on how liquid biopsy can make a difference in the treatment journey of patients. This simple blood test allows for real-time monitoring of tumor changes without the need for invasive procedures. It helps clinicians tailor treatments more effectively and provides patients with more personalized care. Together, we can continue advancing cancer care and supporting those affected by breast cancer by leveraging more modern and less invasive diagnostic technologies. #BreastCancerAwarenessMonth #PinkOctober #LiquidBiopsy #PatientCare

We are delighted to share below a recent GenomeWeb article relating how Hedera Dx is transforming cancer care by leveraging liquid biopsy and real-world data (RWD) to improve patient outcomes. With the launch of Hedera Frame, we are connecting high-quality genomics with deep clinical data to drive adoption of liquid biopsy technologies across hospital laboratories in Europe. Hedera Frame encompasses EMPATHY NSCLC, a prospective, international, multicenter, observational study that is already on its way by recruiting patients across multiple European sites. The study will provide crucial data on the real-world clinical utility of liquid biopsies in guiding treatment decisions. At Hedera Dx, we’re committed to advancing precision oncology, helping both patients and the oncology community by making real-world data insights accessible. Stay tuned for future expansions, including EMPATHY Prostate and EMPATHY Breast, as we continue to innovate for a healthier future! https://lnkd.in/dZwqx9GJ #CancerCare #LiquidBiopsy #RealWorldData #RealWorldEvidence #HealthcareInnovation #CancerResearch

🌟 Hedera Dx Expands RWD Capabilities with EMPATHY NSCLC Study We’re thrilled to announce the launch of Hedera Frame, our AI-enabled real-world data platform, alongside the first patients recruitment for EMPATHY NSCLC—a Prospective, International, Decentralized, Multicenter, Real-World Utility Study for Liquid Biopsy. This groundbreaking initiative will drive deeper insights into treatment outcomes by combining high-quality genomics and clinical data. Together, we will reshape the future of cancer management and patient care. Learn more: https://lnkd.in/ePMhb45y #HealthcareInnovation #CancerCare #LiquidBiopsy #RWD #RWE #NSCLC #AI